Jun 9, 2020Paper

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

BioRxiv : the Preprint Server for Biology
Jesse H ErasmusDeborah Heydenburg Fuller

Abstract

The ongoing COVID-19 pandemic, caused by infection with SARS-CoV-2, is having a dramatic and deleterious impact on health services and the global economy. Grim public health statistics highlight the need for vaccines that can rapidly confer protection after a single dose and be manufactured using components suitable for scale-up and efficient distribution. In response, we have rapidly developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery and immunogenicity. We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a single-dose administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection.

Citations

Sep 20, 2020·Vaccines·Johanna Hettinga, Robert Carlisle
Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Aug 21, 2020·Mucosal Immunology·M D JohansenP M Hansbro
Apr 30, 2021·ILAR Journal·Rebecca T Veenhuis, Caroline J Zeiss
Jul 6, 2021·Journal of Thermal Analysis and Calorimetry·Poornima KalyanramAnju Gupta

❮ Previous
Next ❯

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.